The Calmer Co. has signed a binding heads of agreement with Kaiming Agro Processing to establish a long-term manufacturing partnership, leveraging advanced extraction technology in Fiji to scale its premium botanical ingredients business globally.
- Binding agreement with Kaiming Agro Processing for manufacturing partnership
- New advanced CO2 extraction facility in Fiji to commission December 2026
- Partnership maintains The Calmer Co.'s control over raw materials and brands
- Three-phase framework with potential for equity or joint ventures
- Supports global expansion of kava, ginger, and turmeric extract products
Strategic Partnership to Expand Manufacturing Footprint
The Calmer Co. International Limited (ASX:CCO) has taken a significant step towards scaling its global botanical extract production by entering into a Binding Strategic Partnership Heads of Agreement with Kaiming Agro Processing Pte Ltd’s subsidiary, Pacific Culture and Heritage. This alliance pairs Kaiming’s advanced manufacturing capabilities, including a soon-to-be-commissioned supercritical CO₂ extraction facility in Fiji, with The Calmer Co.'s expertise in premium raw material sourcing, innovation, and international commercialisation.
The partnership aims to accelerate growth in The Calmer Co.'s premium botanical ingredients business and branded consumer products, leveraging a capital-efficient model that avoids duplicative manufacturing investments. Kaiming Agro Processing (KAPPL) will become the preferred manufacturing partner for agreed Fiji-manufactured products, while The Calmer Co. retains control over proprietary formulations, intellectual property, and its globally recognised brands such as Fiji Kava®, Taki Mai®, and Authentic Kava®.
Advanced Manufacturing Facility in Fiji
KAPPL is currently constructing an advanced botanical processing plant in Navua, Fiji, expected to be operational by December 2026. This facility will incorporate cutting-edge supercritical CO₂ extraction technology, positioning it among the most advanced botanical manufacturing sites in Fiji. The new capability complements The Calmer Co.'s existing specialist extraction partners in Australia and India, providing enhanced production flexibility and bringing advanced processing closer to the company’s premium raw material supply chains.
The expanded manufacturing capacity is expected to bolster supply chain resilience, support ongoing product innovation, and increase value-added processing within Fiji. This aligns with The Calmer Co.'s strategy to grow one of its fastest-expanding commercial segments, premium botanical ingredients, while reinforcing Fiji's role as a producer of high-quality botanical products for international markets.
Phased Partnership Framework with Long-Term Potential
The Heads of Agreement outlines a three-phase roadmap for the partnership. Phase One focuses on establishing the manufacturing relationship and transitioning production activities to KAPPL’s new facility, including equipment relocation, quality assurance implementation, and commercial production commencement post-commissioning.
Phase Two contemplates potential acquisition of manufacturing assets by KAPPL, capacity expansion, and operational optimisation, subject to mutual agreement and commercial milestones. Phase Three opens the door to broader strategic integration opportunities such as equity participation, joint ventures, or integration of manufacturing operations, contingent on definitive agreements and regulatory approvals.
Market Opportunity and Strategic Fit
Independent market research cited in the announcement highlights robust growth projections for turmeric, ginger, and kava extract markets globally, with compound annual growth rates between 5.4% and 16.6% over the next decade. The Calmer Co.’s collaboration with KAPPL is designed to capture this momentum by combining complementary strengths: KAPPL’s manufacturing infrastructure and The Calmer Co.’s established commercial platform.
This approach allows The Calmer Co. to focus on areas of competitive advantage such as raw material sourcing, brand development, and international sales, while leveraging KAPPL’s investment in advanced manufacturing technology. The partnership also complements existing manufacturing relationships, providing additional capacity and flexibility as international demand for premium botanical ingredients grows.
Leadership Perspectives on Partnership Impact
CEO Zane Yoshida described the partnership as a milestone that aligns with The Calmer Co.'s long-term growth ambitions, enabling the company to scale without heavy capital expenditure on manufacturing infrastructure. He emphasised the complementary nature of the partnership, which preserves The Calmer Co.'s control over its supply chain and intellectual property while expanding manufacturing capability.
Kaiming Agro Processing Managing Director Calvin Qiu expressed confidence that the partnership would strengthen Fiji’s reputation as a premium botanical product hub and create significant growth opportunities for both companies. KAPPL’s investment in advanced processing infrastructure is seen as a natural fit with The Calmer Co.’s global commercial reach and innovation pipeline.
Capital Raising Context and Next Steps
This announcement follows The Calmer Co.'s recent $3.5 million renounceable entitlement offer, which aims to fund debt repayment, inventory growth, marketing, and product launches, supporting the company’s expansion plans in key markets including the US and Australia. The partnership with KAPPL is expected to enhance operational capacity to meet increasing demand generated by these initiatives.
The parties will now negotiate definitive agreements covering equipment leases, contract manufacturing, quality standards, and performance targets, with Phase One implementation contingent on the commissioning of KAPPL’s facility and satisfaction of operational readiness conditions.
Bottom Line?
The Calmer Co.’s strategic partnership with Kaiming Agro Processing positions it to scale premium botanical extract production efficiently, but execution hinges on facility commissioning and final agreements.
Questions in the middle?
- Will commissioning of KAPPL’s advanced facility proceed on schedule by December 2026?
- How will The Calmer Co. balance integration of KAPPL’s manufacturing with existing partners in Australia and India?
- Could later phases of the partnership lead to equity stakes or joint ventures, and what might that mean for shareholder value?